CHEKHTITSKIJ Verngard (DE),ЧЕХТИЦКИЙ Вернгард (DE),UESTON Dzhon (DE),УЭСТОН Джон (DE),RAKELMANN Nils (DE),РАКЕЛЬМАНН Нильс (DE),KRAFT Folker (DE),КРАФТ Фолькер (DE),ARNDT Petra (DE),АРНДТ Петра (DE),V,CHEKHTITSKIJ Verngard,ЧЕХТИЦКИЙ Вернгард,UESTON Dzhon,УЭСТОН Джон,RAKELMANN Nils,РАКЕЛЬМАНН Нильс,KRAFT Folker,КРАФТ Фолькер,ARNDT Petra,АРНДТ Петра,VIRT Klaus,ВИРТ Клаус,GEGELYAJN Khajnts,ГЕГЕЛЯЙН Ха
申请号：
RU2015142274
公开号：
RU0002666350C2
申请日:
2014.03.07
申请国别(地区):
RU
年份:
2018
代理人:
摘要：
FIELD: medicine； pharmaceuticals.SUBSTANCE: invention relates to a compound of formula I in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or pharmaceutically acceptable salts thereof, which have the property of inhibiting sodium-calcium exchange (NCX). In formula I, Ar is phenyl which is unsubstituted or contains one or more identical or different substituents R0； R0 is selected from a group comprising halogen, (C1-C6)-alkyl, (C1-C6)-alkyl-O-, (C3-C7)-cycloalkyl-O- and (C3-C7)-cycloalkyl-(C1-C4)-alkyl-O-； R1 is hydrogen or one or more identical or different substituents selected from a group comprising fluorine and (C1-C4)-alkyl； R2 is selected from a group comprising (C1-C6)-alkyl, HO-, (C1-C6)-alkyl-C(O)-O-, Het1-C(O)-O-, R5-N(R6)-, R7-C(O)-N(R8)-, R7-S(O)2-N(R8)-, R9-N(R10)-C(O)-N(R8)- and R5-N(R6)-C(O)-, where (C1-C6)-alkyl is unsubstituted or contains one or more identical or different substituents R20； R3 is selected from a group comprising hydrogen and (C1-C6)-alkyl, where (C1-C6)-alkyl is unsubstituted or contains one or more identical or different substituents selected from phenyl； or groups R2 and R3 together are an oxo group； R4 is hydrogen or one or more identical or different substituents selected from a group comprising halogen and (C1-C4)-alkyl； R5 and R6 are independently selected from a group comprising hydrogen, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C3-C7)-cycloalkyl, Het1 and Het2, where (C1-C6)-alkyl is unsubstituted or contains one or more identical or different substituents R20, and (C3-C7) -cycloalkyl and Het2 are all unsubstituted or contain one or more identical or different substituents R21, and phenyl and Het1 are all unsubstituted or contain one or more identical or different substituents R22； R7 is selected from a group comprising (C1-C6)-alkyl, (C3-C7)-cycloalkyl, phenyl, Het1 and Het2； R8 is selected from hydrogen； R9 is selected from (C1-C6)-alkyl； R10 is selected from hydrogen and (C1-C6)-alkyl； R20 is
